Does prospective statin administration prevent LVEF declines 2 years after doxorubicin treatment in patients with breast cancer and lymphoma?
Prospective statin therapy does not prevent declines in left ventricular ejection fraction at 2 years in patients receiving doxorubicin for breast cancer or lymphoma.
In patients with breast cancer and lymphoma with no existing indication for statin therapy, prospective statin administration did not affect LVEF declines 2 years after doxorubicin. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01988571.).
Hundley et al. (Thu,) studied this question.